CHARLOTTE – Durham biotech Kriya Therapeutics which says it represents “gene therapy redefined,” has raised $150 million for its gene therapy programs.

It has gathered more than $600 million since 2019 with operations in North Carolina and California.

CEO Shankar Ramaswamy is the brother of presidential candidate and biotech investor Vivek Ramaswamy.

“Proceeds from the financing will support the clinical translation of Kriya’s broad pipeline of gene therapies and continued scaling of its engineering, computational and manufacturing platforms,” the company says.

Primary focus areas include:

  • Ophthalmology
  • Nneurology
  • Metabolic disease

“Within each therapeutic area, the Company has strategically focused on addressing prevalent diseases with significant unmet medical needs, validated biological targets, and well-defined clinical endpoints so that it may rapidly achieve proof-of-concept through accelerated translational development,” Kriya says.

More Kirya headlines

RTP-based gene therapy firm Kriya Therapeutics buying another firm, will add to portfolio

Durham gene therapy firm Kriya adds $270M in Series C funding to advance pipeline, expand in Triangle

In announcing the funding, Ramaswamy explained the company’s ambitious agenda:

“We have an ambitious goal to advance gene therapies to highly prevalent diseases that affect millions of people around the world.“In order to make gene therapies a cornerstone of mainstream medicine, we have built a fully integrated engine to overcome industry-wide challenges that have constrained research, development and manufacturing in the field of gene therapy. Our investments in world class infrastructure and talent have supported our ability to move with unprecedented efficiency in the engineering and production of gene therapies—and we look forward to the next chapter of our company’s evolution as we translate our programs into the clinic where they can hopefully help patients in desperate need of better treatment options.”